Voltage‑gated sodium channels were differentially expressed in human normal prostate, benign prostatic hyperplasia and prostate cancer cells

Shan,Bin; Dong,Mei; Tang,He; Wang,Na; Zhang,Jin; Yan,Changqing; Jiao,Xiaocui; Zhang,Hailin; Wang,Chuan

doi:10.3892/ol.2014.2110

Voltage‑gated sodium channels were differentially expressed in human normal prostate, benign prostatic hyperplasia and prostate cancer cells

Authors:
- Bin Shan
- Mei Dong
- He Tang
- Na Wang
- Jin Zhang
- Changqing Yan
- Xiaocui Jiao
- Hailin Zhang
- Chuan Wang
View Affiliations

Affiliations: Department of Pharmacology, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Surgery, The Affiliated Hospital of Hebei Science and Technology University, Shijiazhuang, Hebei 050018, P.R. China, Department of Urology, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei 050011, P.R. China, Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
Published online on: May 2, 2014 https://doi.org/10.3892/ol.2014.2110
Pages: 345-350

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Voltage‑gated sodium channels (VGSCs) are expressed not only in excitable cells but also in numerous metastatic cells, particularly in certain types of cancer cells. In some types of cancer, including prostate cancer, the expression of VGSCs is associated with cancer migration, invasion and metastasis in vivo. However, the detailed expression profiles of VGSC α subunits in normal human prostate, in prostatic hyperplasia and prostatic cancer remain controversial. In the present study, quantitative polymerase chain reaction was used to systematically detect all subtypes of VGSC α subunits in normal human prostate, benign prostatic hyperplasia (BPH) and prostate cancer cells. The expression profile of VGSC α subunits was observed to differ between these cell types. Nav1.5 was the major isoform expressed in normal human prostate tissue, while Nav1.5 and Nav1.2 were the predominant isoforms in BPH tissue. However, in PC‑3 and LNCaP cells, two typical prostate cancer cell lines, Nav1.6 and Nav1.7 were abundantly expressed. By comparing the relative expression levels of Nav1.5, Nav1.6 and Nav1.7 in these cells, the mRNA levels of Nav1.6 and Nav1.7 were identified to be 6- to 27‑fold higher in PC‑3 and LNCaP cells than in either normal or BPH samples (P<0.05); however, Nav1.5 mRNA levels were relatively lower compared with those of Nav1.6 or Nav1.7 in all cells analyzed. To confirm whether Nav1.6 and Nav1.7 expression in cancer cells was functional, a patch‑clamp technique was used to record whole‑cell currents. A tetrodotoxin‑sensitive sodium current was successfully recorded in PC‑3 cells, but not in LNCaP cells. It was concluded that although all types of VGSC α subunits exhibited low expression levels in normal prostate and BPH cells, both Nav1.6 and Nav1.7 were significantly upregulated in the prostate cancer cell lines, suggesting these subtypes may be potential diagnostic markers and therapeutic targets for certain types of prostate cancer in humans.

View Figures

View References

1	Catterall WA: The molecular basis of neuronal excitability. Science. 223:653–661. 1984.
2	Catterall WA: From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 26:13–25. 2000.
3	Antzelevitch C, Brugada P, Borggrefe M, et al: Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 111:659–670. 2005.
4	Veltmann C, Schimpf R, Echternach C, et al: A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. Eur Heart J. 27:2544–2552. 2006.
5	Bennett PB, Yazawa K, Makita N and George AL Jr: Molecular mechanism for an inherited cardiac arrhythmia. Nature. 376:683–685. 1995.
6	Waxman SG: Painful Na-channelopathies: an expanding universe. Trends Mol Med. 19:406–409
7	Oliva M, Berkovic SF and Petrou S: Sodium channels and the neurobiology of epilepsy. Epilepsia. 53:1849–1859. 2012.
8	Brackenbury WJ: Voltage-gated sodium channels and metastatic disease. Channels (Austin). 6:352–361. 2012.
9	Baade PD, Youlden DR and Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 53:171–184. 2009.
10	Diss JK, Stewart D, Pani F, et al: A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis. 8:266–273. 2005.
11	Diss JK, Fraser SP, Walker MM, Patel A, Latchman DS and Djamgoz MB: Beta-subunits of voltage-gated sodium channels in human prostate cancer: quantitative in vitro and in vivo analyses of mRNA expression. Prostate Cancer Prostatic Dis. 11:325–333. 2008.
12	Laniado ME, Lalani EN, Fraser SP, et al: Expression and functional analysis of voltage-activated Na⁺ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol. 150:1213–1221. 1997.
13	Grimes JA, Fraser SP, Stephens GJ, et al: Differential expression of voltage-activated Na⁺ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett. 369:290–294. 1995.
14	Nguyen TP, Wang DW, Rhodes TH and George AL Jr: Divergent biophysical defects caused by mutant sodium channels in dilated cardiomyopathy with arrhythmia. Circ Res. 102:364–371. 2008.
15	Benson DW, Wang DW, Dyment M, et al: Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest. 112:1019–1028. 2003.
16	Sato PY, Musa H, Coombs W, et al: Loss of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myocytes. Circ Res. 105:523–526. 2009.
17	Wang C, Hennessey JA, Kirkton RD, et al: Fibroblast growth factor homologous factor 13 regulates Na⁺ channels and conduction velocity in murine hearts. Circ Res. 109:775–782. 2011.
18	Nomiya T, Tsuji H, Toyama S, et al: Management of high-risk prostate cancer: radiation therapy and hormonal therapy. Cancer Treat Rev. 39:872–878. 2013.
19	Diaz D, Delgadillo DM, Hernández-Gallegos E, et al: Functional expression of voltage-gated sodium channels in primary cultures of human cervical cancer. J Cell Physiol. 210:469–478. 2007.
20	Fraser SP, Diss JK, Chioni AM, et al: Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res. 11:5381–5389. 2005.
21	Hernandez-Plata E, Ortiz CS, Marquina-Castillo B, et al: Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer. Int J Cancer. 130:2013–2023. 2012.
22	Roger S, Besson P and Le Guennec JY: Involvement of a novel fast inward sodium current in the invasion capacity of a breast cancer cell line. Biochim Biophys Acta. 1616:107–111. 2003.
23	Fraser SP, Grimes JA and Djamgoz MB: Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate. 44:61–76. 2000.
24	Abdul M and Hoosein N: Voltage-gated sodium ion channels in prostate cancer: expression and activity. Anticancer Res. 22:1727–1730. 2002.
25	Smith P, Rhodes NP, Shortland AP, et al: Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett. 423:19–24. 1998.
26	Brisson L, Gillet L, Calaghan S, et al: Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. Oncogene. 30:2070–2076. 2011.
27	Carrithers MD, Chatterjee G, Carrithers LM, et al: Regulation of podosome formation in macrophages by a splice variant of the sodium channel SCN8A. J Biol Chem. 284:8114–8126. 2009.
28	Diamandis EP and Yu H: Nonprostatic sources of prostate-specific antigen. Urol Clin North Am. 24:275–282. 1997.
29	Foster CS, Cornford P, Forsyth L, Djamgoz MB and Ke Y: The cellular and molecular basis of prostate cancer. BJU Int. 83:171–194. 1999.
30	de Kok JB, Verhaegh GW, Roelofs RW, et al: DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62:2695–2698. 2002.
31	Chakravarti A and Zhai GG: Molecular and genetic prognostic factors of prostate cancer. World J Urol. 21:265–274. 2003.
32	Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI and Buggy DJ: Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 109:180–187. 2008.